about
Melanized fungi in human diseaseTherapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveLiposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleriEpidemiology of invasive candidiasis: a persistent public health problemTherapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.Cerebral phaeohyphomycosis caused by Fonsecaea monophora.Pharmacological advances in the treatment of invasive candidiasis.Susceptibility of filamentous fungi to voriconazole tested by two microdilution methodsVoriconazole pharmacokinetics in liver transplant recipients.Peripheral eosinophilia and eosinophilic colitis during long-term azole therapy for pulmonary aspergillosisGuidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerScedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy.Aspergillus mastoiditis in a patient with systemic lupus erythematosus: a case reportInvasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case report and review of the literature.A five-year survey of dematiaceous fungi in a tropical hospital reveals potential opportunistic speciesCharacteristics of pathogenic fungi and antifungal therapy in cystic fibrosis.Effects of voriconazole on Cryptococcus neoformans.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theResistance to antifungals that target CYP51.Primary central nervous system phaeohyphomycosis: a review of 101 cases.Topical voriconazole as a novel treatment for fungal keratitis.Antifungal clinical trials and guidelines: what we know and do not knowSaccharomyces boulardii induced sepsis: successful therapy with voriconazole after treatment failure with fluconazole.Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapyEvaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infectionsClinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.A case of pseudomembranous colitis after voriconazole therapy.Aspergillus niger: an unusual cause of invasive pulmonary aspergillosis.Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation.Human pharmacogenomic variations and their implications for antifungal efficacy.Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain.Voriconazole in the management of nosocomial invasive fungal infections.Recommendations for the treatment of fungal pneumonias.The lipid formulations of amphotericin B.Cytotoxicity of voriconazole on cultured human corneal endothelial cellsFungal infections in renal transplant patients.A rare presentation of zygomycosis (mucormycosis) and review of the literatureInvasive aspergillosis in patients with hematologic malignancies.Infections caused by Fusarium species.
P2860
Q24633163-41E13868-AF8F-45AA-9F3F-3DA98CB74883Q27009221-D89B1E43-57E6-45BB-82EC-B07CCC8BD861Q28298468-4FDD6683-951E-4D77-9705-4FB1D7516727Q28304841-3EFCC99F-AECC-40D6-AA57-7B8F1F5926D8Q29616758-387EDE01-8860-4080-8F03-DD9CBC813AC0Q30981299-0826F2B0-FEAF-4C4F-B1F9-56F311711793Q31006560-52705BEF-7781-4616-927E-687EBC022040Q33232599-C562A8BE-F05A-41C4-9F82-09AAB0A1BEF2Q33592487-4143059C-C2BB-48B3-8C46-32898CE17E57Q33613685-B5DC0D58-3582-4E85-B8DE-A6740A260530Q33635247-0A526856-623F-4A51-A765-CE936C62356EQ33650105-DFC9D0FB-5259-4D87-9FF7-4C6CDBB5E0B4Q33824506-78A70A98-FA8E-46E4-80D9-737C7CFBF10BQ33854124-0602AE43-6787-4605-97BA-E10BDF45086EQ33911297-A35BC4F0-A183-427E-8148-EF3DA9094BC7Q34011074-B4DEEBD6-CF6A-4C53-A9CC-BED869891838Q34130445-6DF50BA2-131A-4D79-BB10-CB0286F23B1CQ34142180-B39B6CC7-59A2-450C-B5FC-A7E8D7EA63E2Q34212799-BF0AE6CF-2014-4ACE-AD88-C5210FDE21A9Q34276700-CAFF864C-E2C4-4FA6-8E4D-C544FD497B87Q34286912-C0BCEDDB-2E1D-48E3-AA17-5A00C0966ED0Q34301534-3D413222-836E-4327-A1BA-C38D6DAC0EBFQ34400255-DEC4B704-4BEE-47CE-A0C8-73A270226CC7Q34402342-C9CCF725-7623-4F61-B772-7F36E9F6B883Q34413393-91967613-A75A-4ED9-A070-379F0920CB2BQ34483712-8357D0E4-65D0-4161-90FE-D8CFBB92ECEFQ34505582-15992B0B-E423-49FB-A281-71889A03E4B4Q34631174-C4997728-993A-4F76-B087-73B698F52B16Q34641443-1F5C642B-3835-431A-836F-D7D1A9DEBADEQ34980027-16D4BBA3-5FCD-4413-8FB0-0FF37F3C40E6Q35070838-1AF5DEA5-6139-4788-A911-6816DE1E8F2AQ35152691-4E69DB80-7ABF-4B2A-840C-183630535AA4Q35166823-4245C2F4-9198-40B1-91F3-E60D6CAB3F5BQ35183728-7D3A5F85-9D4C-45AB-9C6B-0C4A14BFDE7BQ35183734-244B5A2A-D7C3-47F1-96C1-22EDE17A25B2Q35270872-57EAED21-7CE7-4EBB-B1B3-3AC109806495Q35387111-C99FEACC-8FEA-4509-99A3-9DF7F487FD25Q35589104-992780CB-21EA-4FF0-A5A0-3B5224EE6107Q35616161-C94FBE51-3F7B-4CAC-A4D2-CA668FF52BB2Q35622021-CFA13EDD-FF43-48D0-ADE0-CD4927913FD0
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Voriconazole: a new triazole antifungal agent.
@ast
Voriconazole: a new triazole antifungal agent.
@en
type
label
Voriconazole: a new triazole antifungal agent.
@ast
Voriconazole: a new triazole antifungal agent.
@en
prefLabel
Voriconazole: a new triazole antifungal agent.
@ast
Voriconazole: a new triazole antifungal agent.
@en
P2860
P356
P1476
Voriconazole: a new triazole antifungal agent.
@en
P2093
Carol A Kauffman
Leonard B Johnson
P2860
P304
P356
10.1086/367933
P407
P577
2003-02-10T00:00:00Z